Comparative Efficacy and Safety of Lixisenatide and Insulin Regimens in the Treatment of Patients with Type 2 Diabetes Mellitus Inadequately Controlled by Basal Insulin: A Systematic Review and Network Meta-Analysis

Abstract

S35 treated with IDet and 357(25.0%) patients treated with rIGlar. The overall rate of all hypoglycemia was 109.4 events/100 patient-year. The rate of all hypoglycemia among patients treated with IGlar, IDet and rIGlar were 117.06, 82.97, and 114.06 respectively. The overall rate of severe hypoglycemia was 12.84 events/100 patientyear. The rate of severe hypoglycemia among patients treated with IGlar, IDet and rIGlar were 4.39, 0.84 and 46.23 respectively. The overall rate of non-severe hypoglycemia was 96.56 events/100 patient-year. The rate of non-severe hypoglycemia among patients treated with IGlar, IDet and rIGlar were 112.66, 82.13 and 67.84 respectively. The rates of all hypoglycemia and severe hypoglycemia were significantly less with IDet than IGlar and rIGlar (all P< 0.05), based on comparison between IDet and IGlar, and comparison between IDet and rIGlar. CONCLUSIONS: Hypoglycemic events in patients treated with basal insulin analogues in China was common. There were differences in rate of hypoglycemic events depending on the basal insulin analogue used, with lowest hypoglycemic risk with IDet.